A Study of LY2510924 and Durvalumab in Participants With Solid Tumors

Inclusion Criteria:

- Phase 1a: Have histologic or cytologic confirmation of advanced solid tumor

- Have at least 1 measurable lesion assessable using standard techniques by Response
Evaluation Criteria in Solid Tumours (RECIST) v1.1

- Have adequate organ function

- Have a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG)
scale

- Have provided tissue from a newly obtained core or excisional biopsy of a tumor lesion
or a recent biopsy defined by ≤3 years since last documented progression of disease

- Have an estimated life expectancy of ≥12 weeks, in the judgment of the investigator

Exclusion Criteria:

- Have a serious concomitant systemic disorder including human immunodeficiency virus
(HIV), active hepatitis B virus (HBV), active HCV, active autoimmune disorder or
disease requiring high dose of steroids

- Have a bowel obstruction, history or presence of inflammatory enteropathy or
extensive intestinal resection or chronic diarrhea

- Have evidence of interstitial lung disease that is symptomatic or may interfere
with the detection or management of suspected drug-related pulmonary toxicity or
active, noninfectious pneumonitis

- Have an active infection requiring systemic therapy

- Have had prior therapy with an anti-programmed cell death 1 (PD-1), anti-PD-L1,
anti-PD-L2, or anticytotoxic T lymphocyte-associated antigen-4 antibody

- Moderate or severe cardiovascular disease

- Have symptomatic or uncontrolled brain metastases, spinal cord compression, or
leptomeningeal disease requiring concurrent treatment

- Have received a live vaccine within 30 days before the first dose of study treatment